Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver

Makoto Fujimoto, Koichi Tsuneyama, Mosaburo Kainuma, Nobuyasu Sekiya, Hirozo Goto, Yasuo Takano, Katsutoshi Terasawa, Carlo Selmi, M. Eric Gershwin, Yutaka Shimada

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Data on the efficacy of herbal compounds are often burdened by the lack of appropriate controls or a limited statistical power. Treatments to prevent the progression of non alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) remain unsatisfactory. A total of 56 rabbits were arrayed into 7 groups fed with standard rabbit chow (SRC), SRC with 1% cholesterol, or each of the five experimental treatments (Kampo formulas 1% keishibukuryogan [KBG], 1% orengedokuto [OGT], and 1% shosaikoto [SST]; vitamin E [VE]; or pioglitazone [PG]) in a 1% cholesterol SRC. We analyzed changes after 12 weeks in plasma and liver lipid profiles, glucose metabolism, adipocytokines, oxidative stress, and liver fibrosis. Data demonstrated that all five treatments were associated with significant amelioration of lipid profiles, oxidative stress, and liver fibrosis compared to no supplementation. KBG was superior to VE and PG in the reduction of liver total cholesterol (P < 0.01) and lipid peroxidase levels (P < 0.05), urinary 8-hydroxy-2′-deoxyguanosine (P < 0.05), hepatic α-smooth muscle actin positive areas (P < 0.01) and activated stellate cells (P < 0.01). In conclusion, there was a statistically significant benefit of Kampo formulas (KBG in particular) on a dietary model of NAFLD/NASH. Future studies need to be directed at the mechanisms in the treatment of NASH.

Original languageEnglish (US)
Pages (from-to)328-337
Number of pages10
JournalExperimental Biology and Medicine
Volume233
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Alcoholic Fatty Liver
Kampo Medicine
pioglitazone
Liver
Fatty Liver
Rabbits
Cholesterol
Vitamin E
Lipids
Liver Cirrhosis
Oxidative Stress
Oxidative stress
Adipokines
Therapeutics
Peroxidase
Smooth Muscle
Actins
Metabolism
Glucose
Muscle

Keywords

  • Adiponectin
  • Alternative medicine
  • Hepatic stellate cells
  • Nonalcoholic steatohepatitis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Fujimoto, M., Tsuneyama, K., Kainuma, M., Sekiya, N., Goto, H., Takano, Y., ... Shimada, Y. (2008). Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver. Experimental Biology and Medicine, 233(3), 328-337. https://doi.org/10.3181/0707-RM-207

Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver. / Fujimoto, Makoto; Tsuneyama, Koichi; Kainuma, Mosaburo; Sekiya, Nobuyasu; Goto, Hirozo; Takano, Yasuo; Terasawa, Katsutoshi; Selmi, Carlo; Gershwin, M. Eric; Shimada, Yutaka.

In: Experimental Biology and Medicine, Vol. 233, No. 3, 03.2008, p. 328-337.

Research output: Contribution to journalArticle

Fujimoto, M, Tsuneyama, K, Kainuma, M, Sekiya, N, Goto, H, Takano, Y, Terasawa, K, Selmi, C, Gershwin, ME & Shimada, Y 2008, 'Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver', Experimental Biology and Medicine, vol. 233, no. 3, pp. 328-337. https://doi.org/10.3181/0707-RM-207
Fujimoto, Makoto ; Tsuneyama, Koichi ; Kainuma, Mosaburo ; Sekiya, Nobuyasu ; Goto, Hirozo ; Takano, Yasuo ; Terasawa, Katsutoshi ; Selmi, Carlo ; Gershwin, M. Eric ; Shimada, Yutaka. / Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver. In: Experimental Biology and Medicine. 2008 ; Vol. 233, No. 3. pp. 328-337.
@article{2632958dee56450e95a9613204596130,
title = "Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver",
abstract = "Data on the efficacy of herbal compounds are often burdened by the lack of appropriate controls or a limited statistical power. Treatments to prevent the progression of non alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) remain unsatisfactory. A total of 56 rabbits were arrayed into 7 groups fed with standard rabbit chow (SRC), SRC with 1{\%} cholesterol, or each of the five experimental treatments (Kampo formulas 1{\%} keishibukuryogan [KBG], 1{\%} orengedokuto [OGT], and 1{\%} shosaikoto [SST]; vitamin E [VE]; or pioglitazone [PG]) in a 1{\%} cholesterol SRC. We analyzed changes after 12 weeks in plasma and liver lipid profiles, glucose metabolism, adipocytokines, oxidative stress, and liver fibrosis. Data demonstrated that all five treatments were associated with significant amelioration of lipid profiles, oxidative stress, and liver fibrosis compared to no supplementation. KBG was superior to VE and PG in the reduction of liver total cholesterol (P < 0.01) and lipid peroxidase levels (P < 0.05), urinary 8-hydroxy-2′-deoxyguanosine (P < 0.05), hepatic α-smooth muscle actin positive areas (P < 0.01) and activated stellate cells (P < 0.01). In conclusion, there was a statistically significant benefit of Kampo formulas (KBG in particular) on a dietary model of NAFLD/NASH. Future studies need to be directed at the mechanisms in the treatment of NASH.",
keywords = "Adiponectin, Alternative medicine, Hepatic stellate cells, Nonalcoholic steatohepatitis",
author = "Makoto Fujimoto and Koichi Tsuneyama and Mosaburo Kainuma and Nobuyasu Sekiya and Hirozo Goto and Yasuo Takano and Katsutoshi Terasawa and Carlo Selmi and Gershwin, {M. Eric} and Yutaka Shimada",
year = "2008",
month = "3",
doi = "10.3181/0707-RM-207",
language = "English (US)",
volume = "233",
pages = "328--337",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "1535-3702",
publisher = "Society for Experimental Biology and Medicine",
number = "3",

}

TY - JOUR

T1 - Evidence-based efficacy of kampo formulas in a model of non alcoholic fatty liver

AU - Fujimoto, Makoto

AU - Tsuneyama, Koichi

AU - Kainuma, Mosaburo

AU - Sekiya, Nobuyasu

AU - Goto, Hirozo

AU - Takano, Yasuo

AU - Terasawa, Katsutoshi

AU - Selmi, Carlo

AU - Gershwin, M. Eric

AU - Shimada, Yutaka

PY - 2008/3

Y1 - 2008/3

N2 - Data on the efficacy of herbal compounds are often burdened by the lack of appropriate controls or a limited statistical power. Treatments to prevent the progression of non alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) remain unsatisfactory. A total of 56 rabbits were arrayed into 7 groups fed with standard rabbit chow (SRC), SRC with 1% cholesterol, or each of the five experimental treatments (Kampo formulas 1% keishibukuryogan [KBG], 1% orengedokuto [OGT], and 1% shosaikoto [SST]; vitamin E [VE]; or pioglitazone [PG]) in a 1% cholesterol SRC. We analyzed changes after 12 weeks in plasma and liver lipid profiles, glucose metabolism, adipocytokines, oxidative stress, and liver fibrosis. Data demonstrated that all five treatments were associated with significant amelioration of lipid profiles, oxidative stress, and liver fibrosis compared to no supplementation. KBG was superior to VE and PG in the reduction of liver total cholesterol (P < 0.01) and lipid peroxidase levels (P < 0.05), urinary 8-hydroxy-2′-deoxyguanosine (P < 0.05), hepatic α-smooth muscle actin positive areas (P < 0.01) and activated stellate cells (P < 0.01). In conclusion, there was a statistically significant benefit of Kampo formulas (KBG in particular) on a dietary model of NAFLD/NASH. Future studies need to be directed at the mechanisms in the treatment of NASH.

AB - Data on the efficacy of herbal compounds are often burdened by the lack of appropriate controls or a limited statistical power. Treatments to prevent the progression of non alcoholic fatty liver disease (NAFLD) to steatohepatitis (NASH) remain unsatisfactory. A total of 56 rabbits were arrayed into 7 groups fed with standard rabbit chow (SRC), SRC with 1% cholesterol, or each of the five experimental treatments (Kampo formulas 1% keishibukuryogan [KBG], 1% orengedokuto [OGT], and 1% shosaikoto [SST]; vitamin E [VE]; or pioglitazone [PG]) in a 1% cholesterol SRC. We analyzed changes after 12 weeks in plasma and liver lipid profiles, glucose metabolism, adipocytokines, oxidative stress, and liver fibrosis. Data demonstrated that all five treatments were associated with significant amelioration of lipid profiles, oxidative stress, and liver fibrosis compared to no supplementation. KBG was superior to VE and PG in the reduction of liver total cholesterol (P < 0.01) and lipid peroxidase levels (P < 0.05), urinary 8-hydroxy-2′-deoxyguanosine (P < 0.05), hepatic α-smooth muscle actin positive areas (P < 0.01) and activated stellate cells (P < 0.01). In conclusion, there was a statistically significant benefit of Kampo formulas (KBG in particular) on a dietary model of NAFLD/NASH. Future studies need to be directed at the mechanisms in the treatment of NASH.

KW - Adiponectin

KW - Alternative medicine

KW - Hepatic stellate cells

KW - Nonalcoholic steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=40149085740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40149085740&partnerID=8YFLogxK

U2 - 10.3181/0707-RM-207

DO - 10.3181/0707-RM-207

M3 - Article

VL - 233

SP - 328

EP - 337

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 1535-3702

IS - 3

ER -